Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Inclusion Criteria:

• Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS]or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)

• Participants with one or more documented relapses within the 2 years beforeScreening with either: a. one relapse which occurred within the last year prior torandomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesionwithin 6 months prior to randomization

• Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 atScreening and Baseline (Day 1). Participants with an EDSS score less than or equalto [<=] 2 at Screening and Baseline (Day 1) are only eligible for participation iftheir disease duration (time since onset of symptoms) is no more than 10 years

• Participants are neurologically stable for >= 30 days prior to both screening andbaseline (Day 1)

• Female participants must be neither pregnant nor breast-feeding or must lackchild-bearing potential (as defined by either: post-menopausal or surgicallysterile), or use an effective method of contraception for the duration of the studyand at least 2 years after study intervention due to the long elimination period forteriflunomide of 2 years, unless the participant undergoes an acceleratedelimination procedure

• Male participants must refrain from donating sperm and/or abstain from intercoursewith women of child-bearing potential or use an effective method of contraceptionfor the duration of the study and at least 2 years after study intervention due tothe long elimination period for teriflunomide of 2 years, unless the participantundergoes an accelerated elimination procedure

• Participants have given written informed consent prior to any study-relatedprocedure

• Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

• Participants diagnosed with Progressive MS, in accordance with the 2017 RevisedMcDonald criteria as follows: a). Participants with Primary Progressive MS. b)Participants with secondary progressive MS without evidence of relapse

• Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 atscreening and Baseline (Day 1)

• Immunologic disorder other than MS, or any other condition requiring oral,intravenous (IV), intramuscular, or intra-articular corticosteroid therapy, with theexception of well-controlled Type 2 diabetes mellitus or well controlled thyroiddisease

• Other protocol defined exclusion criteria could apply.